APA

Fontana D., Mari M., Martinelli A., Boccafoschi C., Magno C., Turriziani M., Maymone S. S., Cunico S. C., Zanollo A., Montagna G., Frongia M. & Jacobellis U. (20030829). 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. : Urologia internationalis.

Chicago

Fontana D, Mari M, Martinelli A, Boccafoschi C, Magno C, Turriziani M, Maymone S S, Cunico S Cosciani, Zanollo A, Montagna G, Frongia M and Jacobellis U. 20030829. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. : Urologia internationalis.

Harvard

Fontana D., Mari M., Martinelli A., Boccafoschi C., Magno C., Turriziani M., Maymone S. S., Cunico S. C., Zanollo A., Montagna G., Frongia M. and Jacobellis U. (20030829). 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. : Urologia internationalis.

MLA

Fontana D, Mari M, Martinelli A, Boccafoschi C, Magno C, Turriziani M, Maymone S S, Cunico S Cosciani, Zanollo A, Montagna G, Frongia M and Jacobellis U. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. : Urologia internationalis. 20030829.